Alzheimer's disease is the second biggest killer of Australians, but investors have just bet $5.3 million that a local listed company has the cure.
Actinogen backdoor-listed on the Australian Stock Exchange in 2014 in order to buy the global licence for Xanamem, a drug said to block the excess production of the hormone cortisol in the brain, from Edinburgh University.
Loading...
Michael Bailey writes on arts and culture, and edits Weekend Fin. He is a former editor of the Financial Review Rich List. He is based in Sydney. Connect with Michael on Twitter. Email Michael at m.bailey@nine.com.au
